New Brunswick Government Introduces Biosimilars Switch Policy to Improve Patient Access to Safe and Effective Medicine
Shots:
- New Brunswick joins British Columbia and Alberta in implementing a “switch” policy that changes coverage for specific biologic medicines
- Patients switching from reference biologics to biosimilar versions will continue receiving safe- effective treatment and will enable to save millions of dollars once implemented
- Sandoz is committed to supporting patients- their HCPs- and the New Brunswick Government with high quality biosimilar medicines and experienced- comprehensive patient support programs
Ref: Sandoz | Image: Sandoz
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.
